These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32515227)

  • 1. Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.
    Pawnikar S; Miao Y
    Future Med Chem; 2020 Jul; 12(13):1213-1225. PubMed ID: 32515227
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
    Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
    J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4-targeted PET imaging using
    Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
    Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
    [No Abstract]   [Full Text] [Related]  

  • 4. Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.
    Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
    J Mol Graph Model; 2015 Jul; 60():1-14. PubMed ID: 26080355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based development of antagonists for chemokine receptor CXCR4.
    Zhang C; Hou T; Feng Z; Li Y
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats.
    Mason B; Calhoun C; Woytowicz V; Pina L; Kanda R; Dunn C; Alves A; Donaldson ST
    PLoS One; 2021; 16(3):e0247707. PubMed ID: 33647040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
    Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
    Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing the Positive Binding Cooperativity Mechanism between the Orthosteric and the Allosteric Antagonists of CCR2 by Metadynamics and Gaussian Accelerated Molecular Dynamics Simulations.
    An X; Bai Q; Bing Z; Liu H; Zhang Q; Liu H; Yao X
    ACS Chem Neurosci; 2020 Feb; 11(4):628-637. PubMed ID: 31968162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
    Zhang C; Du C; Feng Z; Zhu J; Li Y
    Chem Biol Drug Des; 2015 Feb; 85(2):119-36. PubMed ID: 24923360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological blockers of CCR5 and CXCR4 improve recovery after traumatic brain injury.
    Friedman-Levi Y; Liraz-Zaltsman S; Shemesh C; Rosenblatt K; Kesner EL; Gincberg G; Carmichael ST; Silva AJ; Shohami E
    Exp Neurol; 2021 Apr; 338():113604. PubMed ID: 33453212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Peptide Agonist Binding in CXCR4 Chemokine Receptor.
    Pawnikar S; Miao Y
    Front Mol Biosci; 2022; 9():821055. PubMed ID: 35359589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.
    Zhu S; Meng Q; Schooley RT; An J; Xu Y; Huang Z
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31412600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.
    Kawatkar SP; Yan M; Gevariya H; Lim MY; Eisold S; Zhu X; Huang Z; An J
    Exp Biol Med (Maywood); 2011 Jul; 236(7):844-50. PubMed ID: 21697335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches.
    Xu L; Li Y; Sun H; Li D; Hou T
    Mol Biosyst; 2013 Aug; 9(8):2107-17. PubMed ID: 23702796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.
    Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
    J Mol Graph Model; 2012 Sep; 38():123-36. PubMed ID: 23079643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.
    Pan WL; Wang Y; Hao Y; Wong JH; Chan WC; Wan DC; Ng TB
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3837-3846. PubMed ID: 30251699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.
    Ngamsri KC; Jans C; Putri RA; Schindler K; Gamper-Tsigaras J; Eggstein C; Köhler D; Konrad FM
    Front Immunol; 2020; 11():407. PubMed ID: 32210974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor CXCR4 activates the RhoA/ROCK2 pathway in spinal neurons that induces bone cancer pain.
    Xu H; Peng C; Chen XT; Yao YY; Chen LP; Yin Q; Shen W
    Mol Pain; 2020; 16():1744806920919568. PubMed ID: 32349612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of chemokine receptor CXCR4 in monomeric and dimeric state with its endogenous ligand CXCL12: coarse-grained simulations identify differences.
    Cutolo P; Basdevant N; Bernadat G; Bachelerie F; Ha-Duong T
    J Biomol Struct Dyn; 2017 Feb; 35(2):399-412. PubMed ID: 26813575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.